Trade Protagonist Therapeutics Inc - PTGX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 38.42 |
| Open | 38.81 |
| 1-Year Change | 42.89% |
| Day's Range | 38.47 - 39.56 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 38.66 | 0.39 | 1.02% | 38.27 | 39.62 | 38.00 |
| Feb 20, 2025 | 38.42 | 0.46 | 1.21% | 37.96 | 38.98 | 37.82 |
| Feb 19, 2025 | 38.45 | 0.70 | 1.85% | 37.75 | 38.57 | 37.41 |
| Feb 18, 2025 | 37.67 | -0.68 | -1.77% | 38.35 | 38.89 | 37.50 |
| Feb 14, 2025 | 38.58 | 0.70 | 1.85% | 37.88 | 39.19 | 37.88 |
| Feb 13, 2025 | 38.55 | 1.06 | 2.83% | 37.49 | 38.60 | 37.20 |
| Feb 12, 2025 | 37.34 | 1.06 | 2.92% | 36.28 | 37.43 | 36.14 |
| Feb 11, 2025 | 36.93 | -0.74 | -1.96% | 37.67 | 37.94 | 36.61 |
| Feb 10, 2025 | 37.94 | -1.06 | -2.72% | 39.00 | 39.36 | 37.64 |
| Feb 7, 2025 | 38.81 | 1.10 | 2.92% | 37.71 | 39.60 | 37.71 |
| Feb 6, 2025 | 37.67 | 0.27 | 0.72% | 37.40 | 39.16 | 37.40 |
| Feb 5, 2025 | 38.36 | 0.83 | 2.21% | 37.53 | 38.47 | 37.53 |
| Feb 4, 2025 | 37.51 | 0.38 | 1.02% | 37.13 | 38.23 | 36.80 |
| Feb 3, 2025 | 37.15 | 0.19 | 0.51% | 36.96 | 37.34 | 36.38 |
| Jan 31, 2025 | 37.69 | -1.12 | -2.89% | 38.81 | 39.45 | 37.49 |
| Jan 30, 2025 | 39.06 | 1.27 | 3.36% | 37.79 | 39.35 | 37.78 |
| Jan 29, 2025 | 38.13 | 0.57 | 1.52% | 37.56 | 38.71 | 37.56 |
| Jan 28, 2025 | 37.94 | 0.09 | 0.24% | 37.85 | 39.16 | 37.76 |
| Jan 27, 2025 | 38.25 | 0.60 | 1.59% | 37.65 | 39.80 | 37.47 |
| Jan 24, 2025 | 37.58 | 0.05 | 0.13% | 37.53 | 38.54 | 36.75 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Protagonist Therapeutics, Inc. Company profile
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Protagonist Therapeutics Inc revenues decreased 4% to $27.4M. Net loss increased 90% to $125.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 66% to $117M (expense), General and administrative - Balancin increase of 33% to $19.8M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com